BGLC - צמיחת הכנסות ב-12 חודשים נגררים BioNexus Gene Lab

BioNexus Gene Lab Corp. leverages Malaysia's neutrality to successfully penetrate BRICS markets, although trade barriers and logistical disruptions could compress its margins. The YoY revenue growth trend for the TTM helps assess shock resilience, where the value -66.70 reflects the current figure. The high scalability of the biomarker platform ensures profitability with minimal testing costs.

This metric is calculated as the percentage change in revenue over the last 12 months relative to the same period last year. This metric determines the business's ability to expand its market presence while excluding market volatility. For BioNexus Gene Lab Corp. (BGLC), these data are critical due to regulatory restrictions in Southeast Asia and scaling complexities. The 12-month revenue growth rate year-over-year clearly demonstrates the effectiveness of overcoming these barriers.